Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug ...

Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential ...

Life sciences leaders are awaiting outcomes of the Section 232 investigation concerning the national security implications of importing pharmaceuticals and related ingredients, which include finished ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

On this episode of the Business of Biotech, host Ben Comer speaks with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo ...